Popular obesity medications semaglutide, sold as Ozempic and Wegovy by Novo Nordisk, and tirzepatide, sold as Mounjaro and Zepbound by Eli Lilly, retain measurable therapeutic efficacy even at low starter doses, according to a study published on August 31, 2026, in Biology Methods & Protocols. The study analyzed health data from 534 patients on a 0.25-milligram semaglutide starter dose and 534 patients on a 2.5-milligram tirzepatide starter dose, each maintained for at least six months without escalation.
At the one-year mark, patients maintained on these lowest approved starter doses experienced an average weight loss of 5.5 percent with tirzepatide and 2.2 percent with semaglutide. This contrasts with average weight loss percentages of 20.2 percent for tirzepatide and 13.7 percent for semaglutide observed at one year with recommended higher maintenance doses in earlier head-to-head clinical trials. While low doses showed verifiable efficacy, patients on starter doses are unlikely to achieve the double-digit weight loss seen with higher doses.
Venky Soundararajan of data analytics firm nference and study leader stated that the finding that patients who never escalated past the initiation dose still lost some weight suggests the drugs have a measurable pharmacologic effect well below the maintenance doses that clinical trials have been built around.
Patients on low starter doses experienced side effects, though with significantly less nausea than those who graduated to higher manufacturer-recommended doses. However, the study recorded differential safety signals between the two treatments. Low-dose tirzepatide was associated with higher rates of kidney injury after two years, occurring in 2.7 percent of patients compared to 0.4 percent of patients taking semaglutide.
The study was observational and not a randomized controlled trial specifically designed to test microdosing strategies. Further research is required to confirm these findings in broader populations and to understand long-term implications.
Previous clinical trials for GLP-1 receptor agonists, such as STEP 10 for semaglutide and SURMOUNT-5 for tirzepatide, demonstrated average weight loss of 15 to 19 percent at higher recommended doses over 68 to 72 weeks. The new study provides a baseline comparison to established higher-dose outcomes, quantifying the difference in efficacy at lower starter tiers.
For patients struggling with obesity who face challenges with tolerability, access, cost, or supply constraints regarding higher doses, the findings suggest that low starter doses can offer modest weight loss benefits. This dynamic could encourage more flexible prescribing practices and broader access to these therapies, while reinforcing that substantial weight loss still requires dose titration.
